Author

Xiaowen Liang

ORCID 0000-0002-6174-2951Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Xiaowen Liang1 paper · Qingdao Agricultural University

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Adela M. Aldana· 1 shared Bin Tang YangiD· 1 shared Jake Jianjun WeniD· 1 shared Jianghua TuiD· 1 shared Jie Cui· 1 shared Jin WangiD· 1 shared Li LiiD· 1 shared Ling WuiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Adela M. Aldana

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacology & ToxicologyJournal of Medicinal ChemistryPeer-reviewedApr 9, 2026

RSPO2-based peptibodies conjugated with pyrrolobenzodiazepine dimer or camptothecin analogs demonstrate potent anti-tumor activity by targeting the three receptors LGR4/5/6 in colorectal cancer and neuroblastoma

Yukimatsu Toh, Jianghua Tu, Ling Wu…·Qingyun J. Liu

The paper develops RSPO2-based peptibody-drug conjugates that target LGR4/5/6 receptors, showing potent anti-tumor activity in colorectal cancer and neuroblastoma models.

1 citation

𝕏 PostBluesky